Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Wednesday that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TAR-200 for the treatment of BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
The FDA is reviewing the application through its Real-Time Oncology Review (RTOR) programme for faster approval.
TAR-200 is the first and only intravesical drug releasing system for this condition and offers an alternative to radical cystectomy, a surgery that removes the entire bladder.
Clinical data from the Phase 2b SunRISe-1 study showed an 83.5% complete response rate with high durability.
TAR-200 is administered in an outpatient setting and has a low rate of severe side effects.
The FDA granted Breakthrough Therapy Designation to TAR-200 in December 2023.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval